Multisystem inflammatory syndrome in children (MIS-C): Implications for long COVID

Inflammopharmacology. 2023 Oct;31(5):2221-2236. doi: 10.1007/s10787-023-01272-3. Epub 2023 Jul 17.

Abstract

The COVID-19 pandemic caused by the coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2) has significantly affected people around the world, leading to substantial morbidity and mortality. Although the pandemic has affected people of all ages, there is increasing evidence that children are less susceptible to SARS-CoV-2 infection and are more likely to experience milder symptoms than adults. However, children with COVID-19 can still develop serious complications, such as multisystem inflammatory syndrome in children (MIS-C). This narrative review of the literature provides an overview of the epidemiology and immune pathology of SARS-CoV-2 infection and MIS-C in children. The review also examines the genetics of COVID-19 and MIS-C in children, including the genetic factors that can influence the susceptibility and severity of the diseases and their implications for personalized medicine and vaccination strategies. By examining current evidence and insights from the literature, this review aims to contribute to the development of effective prevention and treatment strategies for COVID-19, MIS-C, and long COVID syndromes in children.

Keywords: COVID; Children; Long-COVID; MIS-C.

Publication types

  • Review

MeSH terms

  • Adult
  • COVID-19*
  • Child
  • Humans
  • Pandemics
  • Post-Acute COVID-19 Syndrome
  • SARS-CoV-2

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related